Pacira Biosciences Inc
NASDAQ:PCRX
Pacira Biosciences Inc
Revenue
Pacira Biosciences Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Pacira Biosciences Inc
NASDAQ:PCRX
|
Revenue
$675m
|
CAGR 3-Years
16%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$85.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$55.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$35.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
Pacira Biosciences Inc
Revenue Breakdown
Breakdown by Geography
Pacira Biosciences Inc
Breakdown by Segments
Pacira Biosciences Inc
Total Revenue:
675m
USD
|
Net Product Sales:
672.2m
USD
|
Exparel:
538.1m
USD
|
Zilretta:
111.1m
USD
|
Iovera°:
19.7m
USD
|
Bupivacaine Liposome Injectable Suspension:
3.3m
USD
|
Royalty Revenue:
2.7m
USD
|
See Also
What is Pacira Biosciences Inc's Revenue?
Revenue
675m
USD
Based on the financial report for Dec 31, 2023, Pacira Biosciences Inc's Revenue amounts to 675m USD.
What is Pacira Biosciences Inc's Revenue growth rate?
Revenue CAGR 10Y
23%
Over the last year, the Revenue growth was 1%. The average annual Revenue growth rates for Pacira Biosciences Inc have been 16% over the past three years , 15% over the past five years , and 23% over the past ten years .